Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
$267m Deal Expands Biotech’s Research
Executive Summary
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
You may also be interested in...
COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
CEOs Face Grilling On Vaccine Supply In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Real-World Data Confirm Pfizer and AZ COVID-19 Vaccine Efficacy – And Bolster UK Dosing Policy
Observational studies from the National Health Service show encouraging signs for the UK’s vaccination program.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports